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Abstract
Background: In resource-limited settings where viral load (VL) monitoring is scarce or unavailable, clinicians must use
immunological and clinical criteria to define HIV virological treatment failure. This study examined the performance of World
Health Organization (WHO) clinical and immunological failure criteria in predicting virological failure in HIV patients
receiving antiretroviral therapy (ART).
Methods: In a HIV/AIDS program in Busia District Hospital, Kenya, a retrospective, cross-sectional cohort analysis was
performed in April 2008 for all adult patients (.18 years old) on ART for $12 months, treatment-naive at ART start,
attending the clinic at least once in last 6 months, and who had given informed consent. Treatment failure was assessed per
WHO clinical (disease stage 3 or 4) and immunological (CD4 cell count) criteria, and compared with virological failure (VL
.5,000 copies/mL).
Results: Of 926 patients, 123 (13.3%) had clinically defined treatment failure, 53 (5.7%) immunologically defined failure, and
55 (6.0%) virological failure. Sensitivity, specificity, positive predictive value, and negative predictive value of both clinical
and immunological criteria (combined) in predicting virological failure were 36.4%, 83.5%, 12.3%, and 95.4%, respectively.
Conclusions: In this analysis, clinical and immunological criteria were found to perform relatively poorly in predicting
virological failure of ART. VL monitoring and new algorithms for assessing clinical or immunological treatment failure, as
well as improved adherence strategies, are required in ART programs in resource-limited settings.
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Introduction
Substantial progress has been made over the last several years in
the number of people receiving antiretroviral therapy (ART) for
HIV/AIDS treatment. From a baseline of approximately 400,000
people receiving ART in low- and middle-income countries
(LMICs) in December 2003, more than 5 million people were
receiving treatment by the end of 2009 [1,2,3]. Scale-up in sub-
Saharan Africa was most dramatic: from 100,000 people on ART
at the end of 2003 to 3.9 million people at the end of 2009 [3].
Despite these extraordinary gains, global coverage of ART in
LMICs remains at 36% of the estimated overall need at the end of
2009 [3].
High mortality in the early months of treatment [4] and low
rates of retention [5] remain problematic for resource-poor
settings. However, immunological, virological, and survival
outcomes are encouraging in LMICs [6,7]. The public health
approach promoted by World Health Organization (WHO)
allowed the expansion of treatment [8,9], but led to new
challenges, such as early and accurate detection of treatment
failure.
In LMICs where routine viral monitoring is limited, clinicians
follow WHO recommendations to define treatment failure
[8,9,10]. Lack of access to viral load (VL) testing in most LMICs
has led to dependence on clinical and immunological markers to
detect treatment failure, an increasing problem in the era of
‘‘switch from D4T to TDF’’ as recommended by WHO. Concerns
surround the ‘‘limitations of clinical and immunological monitor-
ing for diagnosing treatment failure’’ and ‘‘premature or
unnecessary switching to expensive second-line ART [8].’’
In this study we analyzed the performance of WHO criteria for
clinical and immunological failure as surrogate measures for
virological treatment failure in a context where VL testing is not
widely available.
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e49834Methods
Study Population
In 2003, Me ´decins Sans Frontie `res (MSF) began an ART
program in Busia District Hospital, Kenya. Protocols for HIV
testing and treatment followed 2006 WHO and Ministry of Health
(MOH) guidelines. By December 2008, around 2,000 patients
were started on treatment at the district level and 1,500 at the
rural level in primary health clinics.
From April to September 2008 a cross-sectional survey was
conducted. Adults (.18 years old) currently receiving a triple
antiretroviral (ARV) drug regimen classified as standard 1
st line
therapy (e.g. stavudine [d4T] or zidovudine [AZT], lamivudine
[3TC] and either nevirapine [NVP] or efavirenz [EFV]) for $12
months; ARV-naı ¨ve at treatment start; who attended the clinic at
least once within the previous 6 months; and given informed
consent to participate in the study, were considered eligible for the
study.
All patients meeting the inclusion criteria were placed on a list
that was distributed to the clinicians. In addition, a note was added
to the front of the medical file for each included patients. If an
included patient was attending for a routine visit, the risks and
benefits of the study were explained to the patient.
Clinical outcomes were determined based on data routinely
recorded in the patients files using data collection software called
FUCHIA (Follow Up and Care of HIV Infection and AIDS,
Epicentre, Paris France). The data included hospitalization during
ART and the occurrence or recurrence of selected WHO stage 3
or 4 conditions during ARV therapy diagnosed by clinical officers
trained in HIV care including: weight loss of .10%, pulmonary or
extra pulmonary tuberculosis, cryptococcal meningitis, toxoplas-
mosis, chronic herpes simplex infection, Kaposi’s sarcoma (KS),
pneumocystic pneumonia (PCP), HIV wasting syndrome, severe
bacterial infections, recurrent severe bacterial pneumonia, lym-
phoma, persistent oral candidiasis, sepsis/septicaemia, or HIV
encephalopathy.
Diagnostic capacities were limited at Busia Hospital, X-ray and
acid-fast bacilli in sputum smear were available for TB diagnosis;
but specimen culture was unavailable. Lumbar puncture and
cerebrospinal fluid latex test (Crypto-LA, Wampole Laboratories,
Cranberry, NJ) was used for the diagnosis of cryptococcal
meningitis. All other opportunistic infections were diagnosed
based on clinical findings.
Laboratory Procedures
On the day of enrollment, a venous blood sample of 10 mL was
taken from each patient and divided into two parts: one tested for
CD4 cell count at the Busia laboratory using FACSCount flow
cytometry (BD, Franklin Lakes, NJ, USA), and the other sent to
Kenya Medical Research Institute (KEMRI) in Nairobi, Kenya,
where VL testing was performed using NucliSENS EasyQ HIV
Figure 1. Patient cohort study profile.
doi:10.1371/journal.pone.0049834.g001
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detection of 50 copies/mL.
Definition of Treatment Failure
The treatment protocol of the Busia program recommended
measuring CD4 cell count every 6 months and VL in patients with
either clinical or immunological failure any time after 12 months
on ART. Definitions for treatment failure followed 2006 WHO
guidelines. Immunological failure was confirmed with a second
CD4 measurement.
For the study, treatment failure based on CD4 (immunological)
criteria was defined as either CD4 count below the patient’s
baseline measurement at 6 months of therapy, CD4 count less
than 50% of peak measurement at any time after 6 months of
therapy, or CD4,100 cells/mL after 12 months of therapy [9].
Treatment failure based on clinical criteria was defined as the
occurrence of either new or recurrent disease of WHO clinical
stage 3 or 4 at least 6 months after 1
st line treatment initiation [9].
Clinical events were not considered for defining treatment failure if
they occurred in the first 6 months after ART, as defined by
WHO. All clinical events were registered in patient’s files and
entered into the database after each consultation.
Virological failure was assessed by measuring viral load (VL).
WHO defines virological failure as plasma HIV-1 RNA level
.5,000 copies/mL after 6 months of treatment, if adherence is
considered adequate [8,9].
Statistical Analysis
Data were entered in FUCHIA software (Epicentre, Paris,
France) and exported to and analyzed with SPSS version 18
(Chicago, IL, USA). Data variables were tabulated and analyzed
using chi-square and Fisher’s exact tests. P values of ,0.05 were
considered statistically significant.
Ethical Approval
This study was approved by the Ethics Review Boards of MSF
and KEMRI. Only patients who gave informed consent to
participate in the study were included in this analysis.
Results
Study Population
As of the middle of April 2008, 1,037 out of the 3,471 patients
on ART in the MSF Busia HIV/AIDS treatment program were
deemed eligible for the study. Those excluded were 1,115 patients
on ART ,12 months, 344 non-naı ¨ve for ART or started on ART
other than first line, 305 who died, 358 lost to follow up and 312
who were ,18 years old.
After a second analysis of the eligible group, 111 patients were
excluded; 13 patients were non-naı ¨ve or started on ART other
than first line, 71 were lost to follow-up, 14 transferred out during
the study, 4 died, 8 declined to participate, and one was on ART
,12 months, resulting in 926 patients for the analysis. (Figure 1).
Of the patients in the study, 623 (67.3%) were female. At the
start of ART, median age was 38.3 years (interquartile range
[IQR] 32.1–44.6); 724 (76.3%) patients were WHO clinical
disease stage 3 or 4; the median CD4 cell count was 133 cell/mL
[IQR 68–193]; and 255 (27.5%) patients had a body mass index
(BMI) ,18.5 kg/m
2 (Table 1).
Table 1. Baseline cohort characteristics.
Variable Number (%) Median IQR
(N=926)
Demographics
Gender
Female 623 (67.3) – –
Male 303 (32.7)
Age at start of ART (years)
14–19 6 (0.6) 38.3 32.1–44.6
20–29 135 (14.6)
30–39 378 (40.8)
40–49 299 (32.3)
50–59 85 (9.2)
.60 23 (2.5)
Clinical/Immunological/Virological
BMI at start of ART (kg/m
2)
,16 36 (3.9) 20 18.5–22.0
16–18.5 219 (23.7)
.18.5 671 (72.5)
WHO stage at start of ART (n=923)
Stage I 43 (4.7) – –
Stage II 156 (16.9)
Stage III 548 (59.4)
Stage IV 176 (19.1)
CD4 cell count at start of ART
(cells/mL) (n=919)
,100 335 (36.5) 133 68–193
100–199 397 (43.2)
200–299 148 (16.1)
300–399 37 (4.0)
$400 2 (0.2)
Treatment
Initial ART combination
d4T 3TC NVP 892 (96.3) – –
d4T 3TC EFV 32 (3.5)
AZT 3TC NVP 2 (0.2)
AZT 3TC EFV 0 (0.0)
Median time on treatment
(months) (n=926)
Duration on ART – 38 33.8–45.0
IQR, interquartile range; ART, antiretroviral therapy; BMI, body mass index, ARV,
antiretroviral drug.
doi:10.1371/journal.pone.0049834.t001
Table 2. Viral load results of cross-sectional virological survey.
Viral load, copies/mL # patients (%), N924
,50* 650 (70.3%)
50–399 126 (13.6%)
400–1,000 49 (5.3%)
1,000–5,000 44 (4.8%)
.5,000 55 (6.0%)
*Limit of detection.
doi:10.1371/journal.pone.0049834.t002
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median CD4 gain from baseline was 346.4 cells/mL, and median
time on ART was 38 months [IQR 33.8–45.0].
ART regimens administered at time of inclusion were d4T/
3TC/NVP in 892 (96.3%) patients, d4T/3TC/EFV in 32 (3.5%),
and AZT/3TC/NVP in 2 (0.2%), all in standard dosage and
qualified fixed-dose combination as per WHO recommendations.
Treatment Failure
At the time of the study, 123 (13.3%) of 926 patients had
clinically defined treatment failure, 53 (5.7%) experienced
treatment failure based on CD4 cell count criteria, and 55
(6.0%) had virological failure (VL .5,000 copies/mL) per 2010
WHO definition (Table 2).
Of the patients with clinical failure, 49 (39.8%) had weight loss
of .10%, and 73 (59%) had tuberculosis. Opportunistic infections
were common; bacterial pneumonia, was reported in 16 (13%)
Table 3. Characteristics of patients with and without virological failure at the time of the study.
Patients without virological failure (,5.000 copies/ml) Patients with virological failure (.5.000 copies/ml)
Variable Number (%) Median IQR Variable Number (%) Median IQR p value OR (CI)
(N=869) (N=55)
Demographics Demographics
Gender Gender
Female 587 (67.5) – – Female 34 (61.8) – – 0.38 0.78 (0.44–1.36)
p=0.38
Male 282 (32.5) Male 21 (38.2)
Age at start of ART (years) Age at start of ART (years)
14–19 3 (0.3) 38.5 32.1–44.6 14–19 3 (5.5) 32.4 28.2–44.8 ,0.01 1.76 (1.28–2.42)
p,0.01
20–29 120 (13.8) 20–29 15 (27.3)
30–39 357 (41.1) 30–39 21 (38.2)
40–49 284 (32.7) 40–49 13 (23.6)
50–59 83 (9.6) 50–59 2 (3.6)
.60 22 (2.5) .60 1 (1.8)
Clinical/Immunological/Virological Clinical/Immunological/Virological
Weight at start of ART (kg) Weight at start of ART (kg)
,40 28 (3.2) 55 49–61 ,40 3 (5.5) 58 49–64 0.1 0.98 (0.95–1.00)
p=0.1
40–59 567 (65.2) 40–59 28 (50.9)
60–79 257 (29.6) 60–79 21 (38.2)
80–99 16 (1.8) 80–99 3 (5.5)
.100 1 (0.1) .100 0 (0)
BMI at start of ART (kg/m
2) BMI at start of ART (kg/m
2)
,16 35 (4.0) 20 18.5–22.0 ,16 1 (1.8) 20.5 18.5–22.5 0.5 0.98 (0.89–1.07)
p=0.67
16–18.5 204 (23.5) 16–18.5 15 (27.3)
.18.5 630 (72.5) .18.5 39 (70.9)
WHO stage at start of ART (n=866) WHO stage at start of ART (n=55)
Stage I 38 (4.1) – – Stage I 4 (7.3) – –
Stage II 150 (17.0) Stage II 6 (10.9)
Stage III 516 (59.1) Stage III 31 (56.4)
Stage IV 162 (18.3) Stage IV 14 (25.5)
CD4 cell count at start of ART
(cells/mL) (n=55)
CD4 cell count at start of ART
(cells/mL) (n=862)
,100 309 (35.8) 134 68.7–193 ,100 23 (41.8) 116 54–189 0.2 1.00 (0.99–1.01)
p=0.27
100–199 370 (42.9) 100–199 21 (38.2)
200–299 146 (16.9) 200–299 9 (16.4)
300–399 35 (4.1) 300–399 2 (3.6)
$400 2 (0.2) $400 0 (0.0)
doi:10.1371/journal.pone.0049834.t003
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1.6% of the patients.
At time of study, 274/924 (29.7%) of the cohort had detectable
VL (detection limit, 50 copies/mL); 650 (70.3%) had ,50 copies/
ml and 776 (83.9%) did have ,400 copies/ml. Of the patients
with detectable VL, 46% (126/274) had between 50–399 copies/
mL (table 2). Of the 55 patients with VL .5,000 copies/mL, 21
(38.1%) were male; median time on ART was 40 months; 45
(81.8%) were in WHO stage 3 or 4 at the time of ARV start; and
median CD4 count at ART start was 124.6 cells/mL. (Table 3).
Comparison of means and proportions were carried out using
Mann-Whitney U test and chi square test respectively. The
patients who developed a virological failure were statistically
younger than the ones who did not develop it (p,0.01). Year of
ART initiation was significantly associated with a reduced risk of
developing a clinical failure in univariate analysis and it is
remained significant also after adjustment for possible confounders
in multivariate analysis (p,0.01).
For 773 and 873 patients has been possible to draw a Kaplan
Meier analysis respectively from six months of therapy to clinical
and immunological failure. The mean time before developing
clinical failure is 54.5 months (SD 0.48, CI 95%) and for
immunological failure is 58.6 months (SD 0.39, CI 95%). (Figure 2,
3).
Sensitivity, Specificity, and Positive and Negative
Predictive Values
Sensitivity of immunological and clinical WHO criteria to
define treatment failure was 23.6% and 18.2%, respectively,
compared with virological failure (Table 4). When combining
immunological and clinical failure (patient having either one or
both) and comparing with virological outcome, sensitivity was
36.4% for predicting virological failure.
Specificities for immunological, clinical, and both together for
predicting virological failure were 95.4%, 87.0%, and 83.5%,
respectively.
Positive predictive values (PPV) for immunological and clinical
criteria to define virological failure were 24.5% and 8.1%,
respectively. When both criteria were analyzed together, PPV
was 12.3%. Negative predictive values (NPV) were 95.2%, 94.4%,
and 95.4%, respectively, for immunological, clinical, and both
criteria.
Figure 2. Kaplan Meier analysis from six months of therapy to clinical failure.
doi:10.1371/journal.pone.0049834.g002
Clinical and Immunological Criteria in HIV/AIDS
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In our study we found a relatively low proportion of virological
failure (6.0%) following 2010 WHO definition (VL .5000 copies/
ml) in patients on ART for more than 12 months as reported in
other LMICs, supporting the fact that ART can be provided in
resource-poor settings with favorable outcomes [7,11,12].
In this study, the PPV of clinical or immunological monitoring
for detecting virological treatment failure was relatively low. Mee
et al reported a PPV of CD4 count of 36.8% while Kaiser et al
recorded PPV ranging from 9.5%–28.7%. [11,13,14,15,16,17],
which could result in patients with adequate viral suppression
being incorrectly identified as failing treatment and being
unnecessarily switched to second-line therapy [18]. This would
not only reduce treatment options for patients but also potentially
increase costs and make follow-up of patients receiving protease
inhibitors more difficult. An algorithm for determining treatment
failure based on clinical history, hemoglobin level, and CD4 cell
Figure 3. Kaplan Meier analysis from six months of therapy to immunological failure.
doi:10.1371/journal.pone.0049834.g003
Table 4. Sensitivity, specificity, and predictive values of immunological and clinical criteria in identifying virological treatment
failure.
Test TP FNFP TN
Sensitivity,
% (95% CI)
Specificity,
% (95% CI)
Positive predictive
value, % (95% CI)
Negative predictive
value, % (95% CI)
CD4-based immunological failure 13 42 40 829 23.6 (14.4–36.3) 95.4 (93.8–96.6) 24.5 (14.9–37.6) 95.2 (93.5–96.4)
WHO-defined clinical failure 10 45 113 756 18.2 (10.2–30.3) 87.0 (84.6–89.1) 8.1 (4.5–14.3) 94.4 (92.6–95.8)
Combination of both CD4-based
and WHO-defined clinical failure
20 35 143 726 36.4 (24.9–49.6) 83.5 (80.9–85.8) 12.3 (8.1–18.2) 95.4 (93.7–96.7)
TP=true positive, FN=false negative, FP=false positive, TN=true negative.
Results are based in one CD4 and viral load result.
doi:10.1371/journal.pone.0049834.t004
Clinical and Immunological Criteria in HIV/AIDS
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routine clinical care [19].
Low sensitivity of clinical and immunological criteria to define
treatment failure highlights the need for improved methods to
detect treatment failure in the absence of VL testing. In our study,
only 8.1% of patients with clinical failure and 24.5% of those with
immunological failure were found to have virological failure.
Only 3/55 (5.45%) of patients with confirmed virological failure
met both clinical and immunological criteria for treatment failure,
and 35/55 (63%) of the patients with virological failure did not
meet both clinical and immunological definitions of failure,
showing that patients with VL .5,000 copies/mL might not
meet any of the currently used criteria to detect treatment failure.
Many treatment failures may therefore be missed using only
clinical and immunological criteria, which could lead to accumu-
lated resistance in patients who continue on failing regimens.
An evaluation from resources limited countries found no
evidence of improved mortality in programs with viral load test,
though follow-up was short. [20]. On the other hand, several
studies have concluded that clinical indicators and CD4 cell count
are not favorable predictors of virological failure and routine
laboratory monitoring is associated with improved health and
survival when compared with clinical monitoring alone. [14,17,20]
In HIV high-prevalence, resource-poor settings, where task
shifting takes place to scale up ART, sensitive models are needed
to accurately detect treatment failure when VL testing is
unavailable.
These results from a Kenyan ART program also illustrate the
difficulties faced by other African countries in implementing the
new WHO recommendations for ART initiation [8], moving to
improved first-line regimens containing tenofovir (TDF) or
zidovudine (AZT) in patients who have already been treated with
d4T-based regimen and might have treatment failure. In the ideal
scenario of universal access to VL testing, every patient could be
assessed before being switched from a first- to second-line regimen,
but because this is not the case in most resource-limited settings,
many patients might be switched to a regimen which is the only
available second-line therapy in LMICs.
Follow-up of patients with VL measurements seems to be the
only way to adequately monitor the patients, and VL appears to be
the most reliable tool for deciding when to switch failing regimens
for patients [14,17]. In programs with access to VL monitoring,
patients tended to switch treatment earlier and at higher CD4 cell
counts than at sites without VL [21]. Despite the evidence, VL
testing is not yet widely available for monitoring of patients on
ART in resource-poor settings, and no other simple tools exist for
treatment failure detection. New VL assays meeting specifications
for use in resource-constrained settings are urgently needed to
tackle the current needs of ART monitoring and clinical assistance
for treatment decision-making.
A strength of our study was in the assessment of clinical
outcomes since they were systematically collected in patient’s files,
allowing us to examine the correlation between clinical and
immunological criteria together with viral load measurement.
Another strength of the study was that it was done in a routine
ART program in a resource-limited setting including decentralized
rural clinics, which reflects the reality of other sub-Saharan
African countries.
A limitation of the study lay in not being able to analyze
adherence despite the data obtained through questionnaires since
it was impossible to find standard definitions using the current self-
reported and visual-analogue scale. Another study weakness was
the limited diagnostic capacities for the main opportunistic
infections seen in our program, which could bias some of the
clinical events registered.
This study builds on existing literature and builds the case that
clinical and immunologic criteria, given low sensitivity, allow for
individuals to switch to expensive second-line who may not have
true virological failure.
In conclusion, these data illustrate the urgent needs for new or
improved algorithms for measuring clinical or immunological
treatment failure and wider access to VL monitoring in low-
resource settings. Using current WHO immunological and clinical
criteria to determine virological treatment failure is inadequate in
a setting were VL is not widely available and second-line ART
options are limited.
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